39 results about "Drug Implants" patented technology

The invention includes a device for inserting a medicament within a body cavity of a mammal, the device including a cartridge for containing the medicament therein, the cartridge including a housing, a retractable chamber disposed within the housing and having a lumen, a substantially stationary member disposed within the lumen of the retractable chamber and having a uniform cross-section sized to provide a sliding fit within the lumen to provide for retraction of the retractable chamber about the substantially stationary member upon actuation of the device, and means for retracting the retractable chamber about the substantially stationary member while maintaining the substantially stationary member in a substantially stationary position upon actuation of the device; the device further including means for activating the means for retracting the retractable chamber.

The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.

An administration device comprising an array of needles, one or more fluid agents, and at least one hydrogel is described. The device can simultaneously deliver a plurality of fluid agents along respective axes into a tissue. The use of hydrogel leads to constrained delivery of the fluid agents. The constrained delivery of an agent is also achieved by depositing a drug implant into a tissue. The effect of an agent on the tissue can be evaluated thereafter. In addition, the invention is directed to treating muscle diseases by delivering a therapeutic agent in vivo, and the use of reporter tissues for candidate drug evaluation, detecting and characterizing resistance.

The present invention relates to a preparation method, uses and a use method of a dexamethasone implant for kidney, wherein the dexamethasone implant comprises dexamethasone or dexamethasone acetate, a degradable polymer material, and a water soluble auxiliary material. The preparation method comprises: crushing various materials, mixing, carrying out micro-spheroidization, carrying out mold pressing molding, and heating for a certain time at a proper temperature to prepare the cylindrical implant with a diameter of 0.2-0.9 mm and a length of 0.8-4 mm. According to the present invention, the implant has characteristics of smooth surface and uniform drug release in vivo, wherein the time for releasing 90% of the drug is 1 month to 1 year; and the implant can be implanted into the renal sac through a drug implanting needle so as to treat nephrotic syndrome, nephritis and other chronic kidney diseases.

Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

The invention discloses new application of militarine in preparation of heparin antagonist. The molecular formula of the militarine in the invention is C34H46O17 and the chemical name is bis [4-(beta-D-glucopyranosoxy) benzyl]-2-isobutyl malate. The militarine provided by the invention can be prepared into dosage form suitable for clinical application, mainly including injection, granule, capsule, tablet, powder, pill, drug implants and etc. The effect of antagonize heparin is obvious. The pharmacological effect is similar to or identical with protamine. The invention has the advantage of no adverse reactions to human such as allergy and safety, and can be developed into the substitute of the protamine to be applied in clinic with good application prospect.

The invention provides a chemotherapy drug pulse sustained-release implant agent and a preparation method thereof. The sustained-release implant agent comprises a chemotherapy drug active component such as any one of gemcitabine, gemcitabine hydrochloride, doxorubicin, 5-fluorouracil, cisplatin, carboplatin and paclitaxel, and an excipient such as a polylactic-glycolic acid copolymer. The preparation method provided by the invention comprises the following steps of: evenly mixing the chemotherapy drug active component with the excipient in a solvent, and then drying the mixture of the chemotherapy drug active component and the excipient in a vacuum after removing the solvent; and then sequentially crushing, sieving, melting and blending the mixture to obtain the sustained-release implant agent. The sustained-release implant agent provided by the invention has the advantages that a second drug release is carried out after tumor growth is controlled by a first drug release for a certain period, and the local effective concentration of a drug is effectively increased, so that the effect of administering once and releasing twice is achieved, and the side injury caused by secondary drug implanting is avoided.

The present invention provides for pharmaceutical preparations, devices, systems and methods for the treatment of otic diseases and conditions. In various embodiments, the preparations, devices, systems and methods enable sustained drug release for the treatment or prevention of hearing loss, infections, and other pathological conditions of cochlea and inner ear.

The invention relates to the drug implant of radionuclide particles for cancer therapy. The drug implant comprises composition which is composed of radionuclide which can emit Beta rays, and biodegradable high-molecular material. The compounding ratio is as follows: each 0.9-1.1 mg of the biodegradable high molecular material is proportional to radionuclide which can emit Beta rays with the radioactivity of 18.5 to 37.0 MBq. The composition of <32>P-CP and poly-L-lactic acid is taken as the drug implant of the radionuclide particles for the therapy of malignant solid tumors. The preparation method comprises the following steps: selecting colloidal chromic phosphate or calcium phosphate with the radioactive concentration of 3700 to 7400 MBq / ml and the chemical concentration of 0.5 to 4.14 mg / mal as the <32>P-CP, according to the proportion that <32>P-CP: PLLA is 18.5 to 37.0 MBq: 0.9 to 1.1 mg and according to the proportion that each gram of poly-L-lactic acid is proportional to 3 to 6 ml of anhydrous alcohol, adding anhydrous alcohol into the poly-L-lactic acid and mixing, then adding the <32>P-CP and mixing uniformly, obtaining the paste composition, grinding the paste composition to uniformly distribute the radioactivity into the medium, drying the composition at 60 DEG C to 70 DEG C, then further grinding the composition into powder, positioning the powder into a pressing machine, and pressing particles with the diameter of 0.8 to 1 mm and the length of 2 to 4 mm.